COMP <GO>
BLCO vs ABBV // FORWARD P/E MULTIPLE
Bausch + Lomb Corporation (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: BLCO 4
— ABBV 11
▲ FORWARD P/E MULTIPLE LEADER: BLCO
LAST: $20.00 (-1.96%) • MKT CAP: $7.29B
forward-pe
23.0x
LAST: $294.89 (+1.41%) • MKT CAP: $513.86B
forward-pe
113.1x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BLCO VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BLCO | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 41.00% | 70.20% | -29.20 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 0.80% | 29.00% | -28.20 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.1x | 33.3x | -4.20 | BLCO | /valuation <GO> |
| Free Cash Flow Yield | -0.90% | 3.47% | -4.37 | ABBV | /fcf-yield <GO> |
| Operating Margin | 2.20% | 24.60% | -22.40 | ABBV | /operating-margins <GO> |
| Net Profit Margin | -7.10% | 6.90% | -14.00 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 6.50% | 8.60% | -2.10 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.97 | 5.33 | -4.36 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | ABBV | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.10% | 7.40% | -0.30 | BLCO | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 73.8 | 72.8 | +1.07 | BLCO | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.06 | 1.15 | -0.09 | ABBV | /macro-sensitivity <GO> |
| Forward P/E Multiple ACTIVE | 23.0x | 113.1x | -90.10 | BLCO | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.29B | $513.86B | -$506.57B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BLCO REV | ABBV REV | BLCO GROSS % | ABBV GROSS % | BLCO FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $5.10B | $61.16B | 44.0% | 70.2% | -$66.0M | $17.82B |
| FY 2024 | $4.79B | $56.33B | 44.0% | 70.0% | -$59.0M | $17.83B |
| FY 2023 | $4.15B | $54.32B | 44.0% | 44.0% | -$203.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BLCO // BETA 1.06
ABBV // BETA 1.15